About Pioneer Surgical Technology
Pioneer Surgical Technologies designs, manufactures and distributes spinal and orthopedic implants. The company is dedicated to creating medical devices that improve patient outcomes, provide ease of use and reliability for surgeons, and increases cost effectiveness.
Missing: Pioneer Surgical Technology's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Pioneer Surgical Technology's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Pioneer Surgical Technology
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Pioneer Surgical Technology is included in 1 Expert Collection, including Medical Devices.
Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)
Pioneer Surgical Technology Patents
Pioneer Surgical Technology has filed 1152 patents.
Surgical instruments, Shogakukan manga, Orthopedic surgical procedures, Bone fractures, Gobots
Surgical instruments, Shogakukan manga, Orthopedic surgical procedures, Bone fractures, Gobots
Latest Pioneer Surgical Technology News
Oct 30, 2014
RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, reported operating results for the third quarter of 2014 as follows: Quarterly Highlights: Note: Quarter over quarter revenue growth comparisons for the spine, orthofixation, and BGS and general orthopedic businesses mentioned below include revenues from the July 16, 2013 acquisition of Pioneer Surgical Technology (Pioneer). Achieved revenues of $65.2 million, meeting the upper end of our revenue guidance of $64 to $65 million. Achieved adjusted net income per fully diluted share of $0.03, exceeding guidance of $0.02. Achieved revenues of $11.4 million in the sports medicine business, a 19 percent increase over the third quarter of 2013. Achieved revenues of $20.5 million in the spine business, a 16 percent increase over the third quarter of 2013. Achieved revenues of $9.5 million in the orthofixation business, a 41 percent increase over the third quarter of 2013. Achieved revenues of $9.2 million in the BGS and general orthopedic business, a 20 percent increase over the third quarter of 2013. Introduced two new products for the sports medicine business – the PACK™ Precision Allograft Cartilage Instrument Kit and Allowedge™ Bicortical Bone Wedges and Instrument Kit. Worldwide revenues were $65.2 million for the third quarter of 2014 compared to revenues of $54.7 million for the third quarter of 2013, an increase of 19 percent. Domestic revenues were $59.7 million for the third quarter of 2014 compared to revenues of $49.3 million for the third quarter of 2013. International revenues were $5.5 million for the third quarter of 2014 and were comparable to the third quarter of 2013. Our prior year revenues include Pioneer-related revenues for the stub period of July 16, 2013 to September 30, 2013, whereas our current year period includes a full quarter of Pioneer-related revenues. If Pioneer revenues had been included for the third quarter for both 2013 and 2014, worldwide revenues for the third quarter of 2014 would have increased by 13 percent as compared to the third quarter of 2013. “Revenues from the third quarter met our expectations. As anticipated, we saw some impact from seasonality in surgical cases, primarily in international markets, but we were able to offset that with sequential growth in the U.S.,” said Brian K. Hutchison, president and chief executive officer. “We continued to make progress in meeting the goals we shared in our first quarter earnings release – growth in our sports and spine businesses, traction in surgical specialties and expanded distribution of map3® cellular allogeneic bone graft.” For the third quarter of 2014, the company reported a net income applicable to common shares of $1.2 million and net income per fully diluted common share of $0.02, based on 57.5 million fully diluted shares outstanding, compared to net loss applicable to common shares of $9.1 million and net loss per fully diluted common share of $0.16 for the third quarter of 2013, based on 56.4 million fully diluted shares outstanding. On a non-GAAP basis, excluding a severance charge taken in the third quarter of 2014, the company reported adjusted net income applicable to common shares of $1.5 million and adjusted net income per fully diluted common share of $0.03. Fiscal 2014 and Fourth Quarter Outlook Based on results from the first three quarters of the year, the company is narrowing its full year revenue guidance for 2014. The company now expects full year revenues for 2014 to be between $260 million and $261 million, as compared to prior guidance of between $258 million and $261 million. On an adjusted basis, excluding a first quarter inventory purchase accounting adjustment and a third quarter severance charge, the company expects full year adjusted net income per fully diluted common share to be approximately $0.11 based on 57.4 million fully diluted common shares outstanding, as compared to prior guidance of $0.09 to $0.11. For the fourth quarter of 2014, the company expects revenues to be between $68 million and $69 million and net income per fully diluted common share to be approximately $0.04, based on 57.5 million fully diluted shares outstanding. “Results from the first nine months have met or exceeded our expectations and we continue to be optimistic that we can meet our goals for the year,” Hutchison said. “We are focused on delivering a strong fourth quarter and positioning our business for success in 2015.” Conference Call RTI will host a conference call and simultaneous audio webcast to discuss the third quarter results at 8:30 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com . A replay of the conference call will be available on the RTI website following the call. About RTI Surgical Inc. RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com . Forward Looking Statement This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding our anticipated financial results for our third quarter of fiscal year 2014 and our fiscal 2014 and fourth quarter outlook. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the Company's SEC filings may be obtained by contacting the Company or the SEC or by visiting RTI's website at www.rtix.com or the SEC's website at www.sec.gov .
Pioneer Surgical Technology Frequently Asked Questions (FAQ)
When was Pioneer Surgical Technology founded?
Pioneer Surgical Technology was founded in 1992.
Where is Pioneer Surgical Technology's headquarters?
Pioneer Surgical Technology's headquarters is located at 375 River Park Circle, Marquette.
What is Pioneer Surgical Technology's latest funding round?
Pioneer Surgical Technology's latest funding round is Acquired.
How much did Pioneer Surgical Technology raise?
Pioneer Surgical Technology raised a total of $46.8M.
Who are the investors of Pioneer Surgical Technology?
Investors of Pioneer Surgical Technology include RTI Surgical, RC Capital, Pharos Capital Group, CS First Boston, Highlander Partners and 5 more.
Who are Pioneer Surgical Technology's competitors?
Competitors of Pioneer Surgical Technology include Noraker, Cagenix, Expanding Orthopedics, Tornier, SpineForm and 12 more.
Compare Pioneer Surgical Technology to Competitors
TransCorp develops and commercializes minimally invasive surgical instruments and implants for neurosurgical and orthopedic applications.
Autocam Medical manufactures high-precision components, instruments, implants and handpieces for a variety of medical applications. Some of the company's products include implants, instruments, handpieces, and components.
Southern Implants was established in 2006 to commercialize in North America, South America and Asia, dental implant technologies that have been sold in Europe and other parts of the world for over two decades. Southern Implants, with headquarters in Irvine, California, provides implant surgeons and restorative dentists with a broad range of implants and restorative components that work seamlessly with existing systems while offering unique, innovative features that simplify even the most complex clinical challenges. Southern Implants' proprietary products, the MAX and Co-Axis implant systems provide unique therapies which will enable the merged company to differentiate itself competitively and to grow within this large and expanding market. In addition, Southern Implants manufactures a complete line of generic implants. The MAX Implant is an FDA-cleared implant for immediate placement and immediate load in a molar extraction socket. The Co-Axis Implant is the only implant on the market with 12° and 24° angle incorporated into the implant for multiple applications.
Design, manufacturing and marketing of long term implantable medical devices dedicated to bone reconstruction for applications in orthopedic, spinal, dental and skull-maxillo-facial surgeries.The company's main aim is to conceive bioresorbable implants helping surgeons to improve patients' welfare.
ABS Corporation designs and develops minimally invasive technology focused on relieving pain in the knee. Two medial knee implant systems have been developed: The PEEK Mobility Medial Knee Implant and the OrthoGlide Medial Knee Implant.
Diamas Coats offers biocompatible coating services to companies selling body implants, surgical cutters and personal grooming razors
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.